Table 2.
Response evaluation, progression‐free survival, and overall survival of androgen deprivation therapy‐treated patients
| ADT No. of patients = 35a | BSC No. of patients = 43 | |
|---|---|---|
| Response evaluation, no. of patients (%) | ||
| PR | 6 (18) | |
| Stable disease | 11 (32) | |
| PD | 17 (50) | |
| Not evaluable | 1 | |
| Median PFS in months [95% CI] | 4 [3‐5] | |
| Median PFS in patients with PR or stable disease in months [95% CI] | 11 [6‐15] | |
| Median OS in months [95% CI] | 17 [10‐24] | 5 [1‐9] |
Abbreviations: ADT, androgen deprivation therapy; BSC, best supportive care;CI, confidence interval; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response.
The OS for best supportive care patients is also shown.
a
There were 34 evaluable patients.